Answers are grounded in this paper and cite their sources.
Retrospective analysis shows treatment compliance and survival outcomes for breast cancer in women in Bosnia and Herzegovina, indicating potential for improvement.
Timely diagnosis is critical for improving breast cancer outcomes, especially in resource-limited health systems. This study provides the first real-world evidence from Bosnia and Herzegovina on diagnostic and treatment intervals, adherence, and survival in women with breast cancer. We conducted a retrospective analysis of breast cancer cases diagnosed between 2019 and 2023 at the Clinical Centre University of Sarajevo, the largest cancer center in the country, managing approximately 60% of cases in the Federation of Bosnia and Herzegovina. Most patients (78.1%; 95% CI: 73.8–82.3) were diagnosed through self-referral due to symptoms, with 62.4% of cancers detected at stages 1 and 2. The mean patient and system diagnostic intervals were 38.1 days (95% CI: 23.4–52.8) and 38.6 days (95% CI: 29.9–47.3), respectively, with a total diagnostic interval of 70 days (95% CI: 58.9–82.5). Almost all diagnostic procedures had a waiting time of less than ten days. Among all women undergoing surgery, radical mastectomy was performed in 61% (95% CI: 55–66), while among women with stage 1–2 disease, 55% (95% CI: 48–62) underwent radical mastectomy. Treatment duration averaged 3.7 months for chemotherapy (95% CI: 3.4–4.1) and 0.48 months for radiotherapy (95% CI: 0.26–0.69), with higher compliance for radiotherapy (99.5%; 95% CI: 98–100) than chemotherapy (78%; 95% CI: 72–84). Three-year progression-free survival was 85.7%, and overall three-year survival was 86%. Early breast cancer detection and favorable survival can be achieved even in resource-constrained settings.
No takes yet. Share an insight, caveat, or question.
Beslija et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: